
    
      This was a phase IV, interventional, prospective, mono-centric, single arm, uncontrolled,
      open label trial. The study included outpatient affected by Allergic Rhinitis and/or Chronic
      Urticaria, responding to inclusive criteria and able to perform a preliminary driving test on
      F1-high speed simulator (at the simulator centre) without experiencing signs or symptoms of
      intolerance towards the drive simulation (e.g., nausea, vomiting or dizziness etc). Each
      subject underwent 3 ambulatory visits at the hospital site and 3 driving test at the
      simulator centre.
    
  